Financial Ratios Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Equities
300760
CNE100003G67
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 194.81 CNY | -1.12% |
|
-1.96% | -23.60% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 15.4 | 15.34 | 15.33 | 16.19 | 14.79 | |||||
Return on Total Capital | 21.65 | 21.69 | 21.89 | 23.27 | 20.71 | |||||
Return On Equity % | 31.78 | 31.85 | 32.6 | 35.44 | 31.68 | |||||
Return on Common Equity | 31.8 | 31.86 | 32.6 | 35.6 | 33.85 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 64.52 | 64.51 | 63.92 | 65.43 | 62.51 | |||||
SG&A Margin | 21.45 | 20.2 | 20.16 | 20.69 | 18.74 | |||||
EBITDA Margin % | 36.65 | 36.98 | 36.73 | 37.58 | 37.27 | |||||
EBITA Margin % | 35.23 | 35.55 | 35.31 | 36.11 | 35.57 | |||||
EBIT Margin % | 34.52 | 34.68 | 34.28 | 35.1 | 33.69 | |||||
Income From Continuing Operations Margin % | 31.67 | 31.67 | 31.65 | 33.15 | 31.97 | |||||
Net Income Margin % | 31.66 | 31.66 | 31.64 | 33.16 | 31.77 | |||||
Net Avail. For Common Margin % | 31.66 | 31.66 | 31.64 | 33.16 | 31.77 | |||||
Normalized Net Income Margin | 21.74 | 21.88 | 22.34 | 23.48 | 21.66 | |||||
Levered Free Cash Flow Margin | 27.18 | 19.34 | 24.65 | 11.09 | 17.87 | |||||
Unlevered Free Cash Flow Margin | 27.18 | 19.36 | 24.67 | 11.11 | 17.91 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.71 | 0.71 | 0.72 | 0.74 | 0.7 | |||||
Fixed Assets Turnover | 5.4 | 5.46 | 5.32 | 4.81 | 4.02 | |||||
Receivables Turnover (Average Receivables) | 12.97 | 15.17 | 13.64 | 11.71 | 11.23 | |||||
Inventory Turnover (Average Inventory) | 2.57 | 2.47 | 2.89 | 3.02 | 3.15 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.63 | 2.47 | 2.6 | 2.66 | 2.46 | |||||
Quick Ratio | 2.15 | 2 | 2.21 | 2.21 | 1.93 | |||||
Operating Cash Flow to Current Liabilities | 1.08 | 1.04 | 1.03 | 1.09 | 1.19 | |||||
Days Sales Outstanding (Average Receivables) | 28.21 | 24.06 | 26.76 | 31.18 | 32.59 | |||||
Days Outstanding Inventory (Average Inventory) | 142.42 | 147.92 | 126.44 | 120.96 | 116.13 | |||||
Average Days Payable Outstanding | 57.47 | 76.66 | 73.09 | 75.57 | 68.98 | |||||
Cash Conversion Cycle (Average Days) | 113.16 | 95.32 | 80.11 | 76.57 | 79.74 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | - | 0.88 | 0.74 | 0.88 | 0.73 | |||||
Total Debt / Total Capital | - | 0.87 | 0.73 | 0.88 | 0.73 | |||||
LT Debt/Equity | - | 0.56 | 0.44 | 0.55 | 0.44 | |||||
Long-Term Debt / Total Capital | - | 0.56 | 0.43 | 0.54 | 0.43 | |||||
Total Liabilities / Total Assets | 30.07 | 29.22 | 31.55 | 30.44 | 28.04 | |||||
EBIT / Interest Expense | - | 1.01K | 974.01 | 943.42 | 637.34 | |||||
EBITDA / Interest Expense | - | 1.09K | 1.05K | 1.02K | 711.74 | |||||
(EBITDA - Capex) / Interest Expense | - | 929.71 | 874.24 | 811.83 | 610.81 | |||||
Total Debt / EBITDA | - | 0.03 | 0.02 | 0.02 | 0.02 | |||||
Net Debt / EBITDA | -2.06 | -1.6 | -2.04 | -1.4 | -1.18 | |||||
Total Debt / (EBITDA - Capex) | - | 0.03 | 0.03 | 0.03 | 0.03 | |||||
Net Debt / (EBITDA - Capex) | -2.43 | -1.88 | -2.46 | -1.75 | -1.38 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 27 | 20.18 | 20.17 | 15.04 | 5.14 | |||||
Gross Profit, 1 Yr. Growth % | 26.12 | 20.17 | 19.06 | 17.76 | 3.59 | |||||
EBITDA, 1 Yr. Growth % | 43.03 | 20.88 | 18.89 | 17.32 | 4.03 | |||||
EBITA, 1 Yr. Growth % | 44.29 | 20.86 | 18.91 | 17.26 | 3.29 | |||||
EBIT, 1 Yr. Growth % | 45.37 | 20.73 | 18.78 | 17.8 | 0.91 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 42.15 | 20.19 | 20.07 | 20.47 | 1.4 | |||||
Net Income, 1 Yr. Growth % | 42.24 | 20.19 | 20.07 | 20.56 | 0.74 | |||||
Normalized Net Income, 1 Yr. Growth % | 35.56 | 20.96 | 22.71 | 20.9 | -3.01 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 42.24 | 20.27 | 20.5 | 20.42 | 0.79 | |||||
Accounts Receivable, 1 Yr. Growth % | -9.21 | 16.32 | 48.62 | 23.9 | -2.16 | |||||
Inventory, 1 Yr. Growth % | 56.35 | 0.92 | 12.89 | -1.15 | 19.57 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 12.83 | 24.28 | 22.57 | 30.71 | 22.06 | |||||
Total Assets, 1 Yr. Growth % | 29.93 | 14.4 | 22.68 | 2.56 | 18.16 | |||||
Tangible Book Value, 1 Yr. Growth % | 27.97 | -1.12 | 23.84 | 0.77 | -30.07 | |||||
Common Equity, 1 Yr. Growth % | 25.19 | 15.79 | 18.65 | 3.45 | 8.38 | |||||
Cash From Operations, 1 Yr. Growth % | 87.85 | 1.45 | 34.92 | -8.89 | 12.38 | |||||
Capital Expenditures, 1 Yr. Growth % | 52.24 | 18.58 | 36.58 | 40.36 | -27.12 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 131.35 | -14.49 | 53.16 | -48.25 | 69.58 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 131.35 | -14.39 | 53.13 | -48.19 | 69.53 | |||||
Dividend Per Share, 1 Yr. Growth % | 66.67 | 40 | 28.57 | 28.89 | 8.1 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 23.64 | 23.54 | 20.18 | 17.57 | 9.98 | |||||
Gross Profit, 2 Yr. CAGR % | 21.92 | 23.11 | 19.61 | 18.41 | 8.76 | |||||
EBITDA, 2 Yr. CAGR % | 32.62 | 31.71 | 20.1 | 18.29 | 10.61 | |||||
EBITA, 2 Yr. CAGR % | 33.47 | 32.28 | 20.11 | 18.28 | 10.19 | |||||
EBIT, 2 Yr. CAGR % | 33.88 | 32.48 | 19.75 | 18.29 | 9.03 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 33.7 | 30.71 | 20.13 | 20.27 | 10.52 | |||||
Net Income, 2 Yr. CAGR % | 33.79 | 30.75 | 20.13 | 20.31 | 10.21 | |||||
Normalized Net Income, 2 Yr. CAGR % | 32.03 | 28.05 | 21.83 | 21.8 | 8.28 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 28.05 | 30.8 | 20.39 | 20.46 | 10.17 | |||||
Accounts Receivable, 2 Yr. CAGR % | -2.75 | 2.77 | 31.48 | 35.7 | 10.1 | |||||
Inventory, 2 Yr. CAGR % | 44.36 | 26.97 | 5.48 | 5.64 | 8.72 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 10.06 | 18.41 | 23.42 | 26.58 | 26.31 | |||||
Total Assets, 2 Yr. CAGR % | 24.1 | 21.92 | 18.47 | 12.17 | 10.08 | |||||
Tangible Book Value, 2 Yr. CAGR % | 27.4 | 12.49 | 10.66 | 11.71 | -16.05 | |||||
Common Equity, 2 Yr. CAGR % | 23.92 | 20.4 | 17.21 | 10.79 | 5.89 | |||||
Cash From Operations, 2 Yr. CAGR % | 48.27 | 38.05 | 16.99 | 10.87 | 1.19 | |||||
Capital Expenditures, 2 Yr. CAGR % | 32.05 | 34.36 | 27.26 | 38.46 | 1.14 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 72.5 | 40.65 | 14.44 | -10.98 | -6.35 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 71.32 | 40.73 | 14.49 | -10.93 | -6.31 | |||||
Dividend Per Share, 2 Yr. CAGR % | 58.11 | 52.75 | 34.16 | 28.73 | 18.04 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 23.46 | 22.48 | 22.41 | 18.44 | 13.27 | |||||
Gross Profit, 3 Yr. CAGR % | 22 | 21.33 | 21.74 | 18.99 | 12.09 | |||||
EBITDA, 3 Yr. CAGR % | 30.31 | 28.73 | 27.44 | 19.3 | 13.42 | |||||
EBITA, 3 Yr. CAGR % | 31.36 | 29.27 | 27.83 | 19.28 | 13.15 | |||||
EBIT, 3 Yr. CAGR % | 31.7 | 29.35 | 27.74 | 19.09 | 12.18 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 36.8 | 29.03 | 27.06 | 20.24 | 13.62 | |||||
Net Income, 3 Yr. CAGR % | 37 | 29.09 | 27.09 | 20.27 | 13.4 | |||||
Normalized Net Income, 3 Yr. CAGR % | 36.1 | 28.23 | 26.25 | 21.52 | 12.89 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 32.21 | 25.4 | 27.27 | 20.4 | 13.51 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.65 | 3.23 | 16.21 | 28.9 | 21.68 | |||||
Inventory, 3 Yr. CAGR % | 31.21 | 29.04 | 21.13 | 3.22 | 10.09 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 9.96 | 14.61 | 19.78 | 25.81 | 25.05 | |||||
Total Assets, 3 Yr. CAGR % | 32.13 | 20.78 | 22.17 | 12.91 | 14.13 | |||||
Tangible Book Value, 3 Yr. CAGR % | 67.48 | 17.08 | 16.15 | 7.26 | -4.44 | |||||
Common Equity, 3 Yr. CAGR % | 52.06 | 21.15 | 19.82 | 12.43 | 9.98 | |||||
Cash From Operations, 3 Yr. CAGR % | 39.03 | 30.66 | 37 | 7.64 | 11.38 | |||||
Capital Expenditures, 3 Yr. CAGR % | 36.33 | 27.4 | 35.1 | 31.49 | 11.79 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 56.78 | 36.52 | 44.7 | -12.16 | 10.34 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 55.03 | 35.95 | 44.75 | -12.1 | 10.36 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | 51.83 | 44.22 | 32.38 | 21.45 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 21.28 | 22.85 | 22.13 | 20.49 | 17.27 | |||||
Gross Profit, 5 Yr. CAGR % | 22.51 | 23.17 | 21.04 | 20.15 | 16.37 | |||||
EBITDA, 5 Yr. CAGR % | 47.27 | 42.08 | 26.21 | 24.54 | 20.5 | |||||
EBITA, 5 Yr. CAGR % | 52.88 | 44.53 | 26.82 | 24.85 | 20.54 | |||||
EBIT, 5 Yr. CAGR % | 52.26 | 43.81 | 26.78 | 24.8 | 19.9 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 47.92 | 37.78 | 29.87 | 25.45 | 20.17 | |||||
Net Income, 5 Yr. CAGR % | 48.89 | 37.97 | 29.98 | 25.51 | 20.04 | |||||
Normalized Net Income, 5 Yr. CAGR % | 39.38 | 38.47 | 30.2 | 25.62 | 18.73 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 41.08 | 32.55 | 27.34 | 23.4 | 20.13 | |||||
Accounts Receivable, 5 Yr. CAGR % | 4.5 | 11.23 | 13.34 | 15.17 | 13.73 | |||||
Inventory, 5 Yr. CAGR % | 28.73 | 28.77 | 20.76 | 18.55 | 16 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 7.48 | 11.52 | 15.16 | 19.25 | 22.35 | |||||
Total Assets, 5 Yr. CAGR % | 21.92 | 24.04 | 26.49 | 17.26 | 17.18 | |||||
Tangible Book Value, 5 Yr. CAGR % | 38.06 | 55.26 | 41.89 | 14.9 | 2 | |||||
Common Equity, 5 Yr. CAGR % | 29.57 | 42.92 | 37.03 | 16.9 | 14.04 | |||||
Cash From Operations, 5 Yr. CAGR % | 34.38 | 24.24 | 29.76 | 22.35 | 21.36 | |||||
Capital Expenditures, 5 Yr. CAGR % | 14.71 | 27.67 | 32.63 | 31.71 | 20.33 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 45.6 | 36.02 | 38.23 | 15.06 | 21.59 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 44.78 | 34.99 | 37.33 | 14.79 | 21.63 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | - | - | 42.13 | 33.12 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















